Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04585789 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT04585789 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 24 participants.
The verdict
NCT04585789, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to assess changes in intrahepatic hepatitis B surface antigen (HBsAg) between baseline and on-treatment liver biopsy in response to JNJ-3989-based combination treatment.
Interventions
- DRUG Tenofovir alafenamide (TAF)
- DRUG Entecavir (ETV)
- DRUG JNJ-56136379
- DRUG Tenofovir disoproxil
- DRUG JNJ-73763989
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-03-11 |
| Est. Completion | 2024-01-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04585789
The ClinicalTrials.gov registry entry for NCT04585789 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tenofovir alafenamide (TAF) is the first listed.
NCT04585789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04585789 about?
NCT04585789 is a clinical study titled "A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection". The purpose of this study is to assess changes in intrahepatic hepatitis B surface antigen (HBsAg) between baseline and on-treatment liver biopsy in response to JNJ-3989-based combination treatment.
What is the current status of trial NCT04585789?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2021-03-11. Estimated completion is 2024-01-09.
What interventions are being tested in trial NCT04585789?
The interventions under investigation include: Tenofovir alafenamide (TAF) (DRUG), Entecavir (ETV) (DRUG), JNJ-56136379 (DRUG), Tenofovir disoproxil (DRUG), JNJ-73763989 (DRUG).
Who is sponsoring clinical trial NCT04585789?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.